1429022-33-2

Upstream product

• 1429022-32-1 2-benzyloxy-5-aminoacetophenone 
• 98-88-4 benzoyl chloride 
• 1429022-31-0 1-(2-(benzyloxy)-5-nitrophenyl)ethanone 
• 100-44-7 benzyl chloride 
• 96-97-9 5-nitrosalicylic acid 
• 830-03-5 4-nitrophenol acetate 
• 100-02-7 4-nitro-phenol 

Downstream Products

• 1429022-42-3 N-(4-(benzyloxy)-3-(2-bromoacetyl)phenyl)benzamide 
• 1429022-51-4 N-(3-(2-aminothiazol-4-yl)-4-(benzyloxy)phenyl)benzamide 
• 1429022-60-5 N-(3-(2-aminooxazol-4-yl)-4-(benzyloxy)phenyl)benzamide 
• 1429022-65-0 N-(3-(2-amino-6H-1,3,4-thiadiazin-5-yl)-4-(benzyloxy)phenyl)benzamide monohydrobromide 
• 1429172-38-2 N-(3-(2-amino-6H-1,3,4-thiadiazin-5-yl)-4-(benzyloxy)phenyl)benzamide 

Relevant academic research and scientific papers

Design, synthesis and evaluation of 3-(2-Aminoheterocycle)-4- benzyloxyphenylbenzamide derivatives as BACE-1 inhibitors

Three series of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide derivatives, 2-aminooxazoles, 2-aminothiazoles, and 2-amino-6H-1,3,4-thiadizines were designed, synthesized and evaluated as β-secretase (BACE-1) inhibitors. Preliminary structure-activity relationships revealed that the existence of a 2-amino-6H-1,3,4-thiadizine moiety and α-naphthyl group were favorable for BACE-1 inhibition. Among the synthesized compounds, 5e exhibited the most potent BACE-1 inhibitory activity, with an IC50 value of 9.9 μM and it exhibited high brain uptake potential in Madin-Darby anine kidney cell lines (MDCK) and a Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) model.